VanEck Pharmaceutical ETF
50 hedge funds and large institutions have $93M invested in VanEck Pharmaceutical ETF in 2017 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 15 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
32% less capital invested
Capital invested by funds: $136M → $93M (-$43.1M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $339K
Holders
50
Holding in Top 10
–
Calls
–
Puts
$339K
Top Buyers
| 1 | +$7.24M | |
| 2 | +$1.78M | |
| 3 | +$1.3M | |
| 4 |
Morgan Stanley
New York
|
+$1.28M |
| 5 |
Citigroup
New York
|
+$1.04M |
Top Sellers
| 1 | -$67.1M | |
| 2 | -$5.98M | |
| 3 | -$5.93M | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.41M |
| 5 |
CC
Colrain Capital
Boston,
Massachusetts
|
-$578K |